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Background
Omalizumab, a recombinant humanized monoclonal
antibody to IgE, is recommended as a new option for
the treatment of severe persistent allergic asthma. The
purpose of this study is to assess the effects omalizumab
treatment on life quality and its side effects in the severe
persistent asthma patients.
Methods
In this study, we evaluated 19 severe persistent asthma
patients who received therapy with omalizumab for
8 months. Omalizumab was administered every 2 weeks
between the doses of 150 to 375 mg. Symptoms and
severity of allergic reactions were recorded before and
after being on omalizumab. IgE levels, mean platelet
volume (MPV), platelet levels, pulmonary function test
and asthma control test were evaluated in all patients
before and 8 months after the treatment. Local and sys-
temic side effects of omalizumab were evaluated. Stool
parasites were examined at 4th and 8th months after
initiation of treatment to investigate any parasitosis.
Results
The patients had severe persistent asthma for periods
ranging from 3 to 8 years, and they were diagnosed with
allergic asthma for 7-28 years. Thrombocytopenia devel-
oped in a male patient after the 22nd dose of the drug
was given. When the platelet count fell down to 55.000,
the omalizumab treatment was suspended. During the
therapy period, one patient had parasitosis (giardiasis),
one patient had severe side effects, one patient had dys-
pnea two hours after the injection, and one patient had a
dyspnea attack 2 hours after the injection. The changes
in MPV levels were not statistically significant. There was
also significant decrease in IgE levels after the treatment.
Conclusions
Our clinical follow-up study suggesting that monitoring
the complete blood cell count might be important in the
use of omalizumab. Only in one case, a dyspnea attack
occurred 2 hours after the injection. The patient was hos-
pitalized and treated appropriately, and discharged after a
24 hours of follow-up period. Thrombocytopenia devel-
oped in one patient and the treatment was suspended.
Although we did not have any anaphylaxis, we believe
that the patients should be monitored at least for 3 hours
after the Omalizumab injection.
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